Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Protagenic Therapeutics Inc (NQ: PTIX ) 0.6360 UNCHANGED Streaming Delayed Price Updated: 3:55 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 7,470 Open 0.6360 Bid (Size) 0.5836 (1) Ask (Size) 0.6122 (2) Prev. Close 0.6360 Today's Range 0.5799 - 0.6360 52wk Range 0.5000 - 1.870 Shares Outstanding 4,467,266 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 12 Health Care Stocks Moving In Tuesday's Pre-Market Session October 01, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session September 30, 2024 Via Benzinga Performance YTD -30.87% -30.87% 1 Month +5.65% +5.65% 3 Month -25.44% -25.44% 6 Month -60.50% -60.50% 1 Year -42.18% -42.18% More News Read More Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket September 16, 2024 Via Benzinga Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket September 12, 2024 Via Benzinga Protagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston Summit April 17, 2024 Via ACCESSWIRE Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results April 01, 2024 Via ACCESSWIRE PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q2 2024 August 15, 2024 Via InvestorPlace PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q1 2024 June 25, 2024 Via InvestorPlace 12 Health Care Stocks Moving In Thursday's Intraday Session May 23, 2024 Via Benzinga Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders May 22, 2024 Via ACCESSWIRE Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial May 01, 2024 Via ACCESSWIRE Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders March 27, 2024 Via ACCESSWIRE Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call March 25, 2024 Via ACCESSWIRE Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders February 13, 2024 Via ACCESSWIRE Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114 September 26, 2023 Via ACCESSWIRE 12 Health Care Stocks Moving In Friday's Pre-Market Session April 26, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session April 25, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session April 23, 2024 Via Benzinga PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023 April 01, 2024 Via InvestorPlace Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice March 21, 2024 Via ACCESSWIRE Earnings Scheduled For April 1, 2024 April 01, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session March 05, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session December 13, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session October 10, 2023 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session October 04, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.